Fig. 4 | Scientific Reports

Fig. 4

From: Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry

Fig. 4

Overall survival in patients receiving the five most common regimen groups at 1 L. (a) Patients who received ASCT in any LoT. (b) Patients who did not receive ASCT in any LoT. 1 L, first line of therapy; ASCT, autologous stem cell transplantation; LoT, line of therapy. Because no patients who received bortezomib + melphalan in 1 L subsequently received ASCT in any LoT, this regimen is not displayed in panel a. Patients with ASCT-only LoTs are excluded from this output.

Back to article page